Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at the Liver Meeting 2023.

Document Cited in Related
Vincent

ENPNewswire-October 26, 2023--Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at the Liver Meeting 2023

(C)2023 ENPublishing - http://www.enpublishing.co.uk

Release date- 25102023 - GAITHERSBURG - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) will be presented in a late-breaking poster presentation at The Liver Meeting 2023 of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA (November 10-14, 2023).

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).

About Pemvidutide

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT